trials, has not been utilized in treatment of bladder cancer. The purpose of this study was to measure the cell death effect of HAL/Blue light on patient-derived bladder cancer organoids.
INTRODUCTION AND OBJECTIVES: Patient-derived xenografts (PDX) and organoids are potential powerful tools for preclinical testing of novel therapeutics. However, the fidelity of these model systems to the human primary tumor needs to be established. We aim to establish and molecularly characterize a human bladder cancer PDX in vivo and in an organoid system derived from the PDX for preclinical studies.
METHODS: Two-mm3 bits of urothelial carcinoma originated from muscle invasive disease excised in cystectomy were implanted subcutaneously into male severe combined immunodeficient mice to establish PDXs. Established PDXs (CoCaB 1) were passaged subcutaneously in SCID mice and histopathology of each passage was compared with the originating tumor. Tumor size was measured weekly by caliper to determine the growth rate of PDXs from early (P1/P2) through late passage (P8/P9). Representative early and late passages were collected for organoid establishment. For both early and late passages, proliferation was assessed by Ki67 in PDXs and organoids, and cell cycle analysis and MTS assay specifically in organoids. RNA sequencing was performed to compare the fidelity of PDX and organoids vs. primary tumor.
RESULTS: Histologically, 16 of the 16 (100%) PDXs generated from early through late passage (1-2 tumors per passage) were similar to the original high-grade urothelial carcinoma. In vivo, the latency of PDX establishment decreased upon passage (9 weeks to take in early P1/2 vs. 2 weeks to take in late P8/9) and the growth rate increased upon passage. Concordantly, Ki67 proliferation index increased from 40% in P1 to 95% in P8 and was positively correlated with increasing passage (Spearman R¼0.804, p¼0.001) . Similarly, in organoids, late passage demonstrated a shorter growth doubling time, higher Ki67 proliferation index, and faster progression through cell cycle. Transcriptional analysis showed that the PDX contained 81-92% human transcripts, whereas organoids contained >99% human transcripts.
CONCLUSIONS: Bladder cancer PDXs histologically represented the originating disease. PDX and organoid systems demonstrated concordant increase in proliferation upon serial passages, suggesting clonal selection may take place in this aggressive tumor type. Despite more mouse stromal content in PDX, PDX and organoid represent two independent model systems with highly similar biological responses that allow therapeutic studies.
INTRODUCTION AND OBJECTIVES: MiRNAs packed in exosomes (EV) can affect cell-cell communication in the tumor microenvironment and play a crucial role in tumorigenesis. Our aim is the identification of a specific exosomal miRNA expression pattern depending on the invasiveness of urinary bladder cancer (BC) cells. Furthermore we want to characterize their functional role in reprogramming normal bladder fibroblasts (BF).
METHODS: EVs were isolated from invasive (T24,253J-BV,J82), non-invasive (RT112,5637) BC cells and normal bladder cells (HCV29) by ultracentrifugation and were characterized by Western Blot analysis, Nano Particle Tracking Analysis and electron microscopy. Uptake of PKH26-labeled BC-EV by hTERT-immortalized fibroblasts (hTERT-FB) was shown by LSM. EV-mediated miRNA transfer between BC cells and hTERT-FB was analyzed by transfection of BC cells with cel-miR-39, co-cultivation with hTERT-FB and qPCR. Proliferation and migration of EV-treated normal BF were measured by BrdU assay and Boyden Chamber assay.
RESULTS: Electron microscopy images revealed the typical size (61-81 nm) and vesicular structure of EV. Isolated EV exhibited a high amount of exosomal markers (CD81, syntenin) and less presence of contamination marker calreticulin. EV of invasive BC cells are characterized by a specific miRNA signature of 15 miRNAs. Validation of 6 selected miRNAs confirms a significant different expression between both, invasive and non-invasive cells and their EV. miR-30a-3p could be confirmed by qPCR to be significantly deregulated exclusively in EVs of invasive cells compared to the non-invasive counterparts, but not in the Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e717 parental cells. Uptake of labeled EV and exosomal miRNA of BC cells in hTERT-FB could be confirmed. Urinary DNA is promising resources for liquid biopsy in urological malignancies. In this study, we performed genomic profiling of UBC and matched urinary cell free DNA (cfDNA) and exosomal DNA (exoDNA).
METHODS: We included 9 patients who underwent surgery for UBC. Fresh frozen tumor sample and normal blood sample was used for genomic profiling of UBC. We also performed genomic profiling of matched urinary DNA to investigate whether genomic alteration in tumor samples are echoed in urinary DNA. Urinary exoDNA was extracted from urinary exosome which was isolated by ExoQuick and urinary cfDNA was extracted by commercial kit using magnetic bead. We performed 9 gene target sequencing for somatic mutation analysis and low depth whole genome sequencing (ldWGS) for copy number analysis.
RESULTS: We found 17 somatic mutations in 6 patients, and 17 included 6 nonsynonymous SNVs, 3 stopgain SNVs, 2 frameshift deletion and 6 synonymous SNVs. Of 17 somatic mutations, 12 were identified in cfDNA and exoDNA with the mean allele frequency of 54.5% and 65.6%, respectively. Mean depth of cfDNA and exoDNA was 1721X and 1627X, respectively (Figure 1) . In copy number analysis, mean 20.4% of whole genome region was covered by >1X. Copy number plots of cfDNA and exoDNA showed similar pattern with those of tumor samples. When we compare the log2 ratio of 100k bin size in whole genome regions, Pearson correlation coefficients of tumor vs cfDNA (0.481) and tumor vs exoDNA (0.455) were higher than that of tumor vs normal (0.086) (Figure 2) . CONCLUSIONS: Both urinary cfDNA and exoDNA were representative of the entire human genome and allowed genomic profiling of UBC. Specifically, copy number analysis using ldWGS has potential to be used as tools developing biomarker with low cost and whole genome coverage. 
MP54-17 GLUCOCORTICOID RECEPTOR AND FOXO1 EXPRESSION IN BLADDER CANCER AS AN INDEPENDENT PROGNOSTICATOR
Hiroki Ide*, Baltimore, MD; Satoshi Inoue, Taichi Mizushima, Rochester, NY; George Netto, Birmingham, AL; Hiroshi Miyamoto, Rochester, NY INTRODUCTION AND OBJECTIVES: Our preliminary studies suggest that FOXO1, a transcriptional factor known to induce apoptosis through the PI3K-Akt pathway, functions as a tumor suppressor in bladder cancer. Meanwhile, cross-talk between FOXO1 and glucocorticoid receptor (GR) signals has been demonstrated in non-urothelial cancer cells. The current study aims to determine the association between FOXO1 and GR expression in bladder cancer and its prognostic significance.
METHODS: We immunohistochemically stained for GR, FOXO1, and p-FOXO1 (a phosphorylated/inactive form), in bladder cancer tissue microarrays consisting of 51 low-grade non-muscleinvasive, 27 high-grade non-muscle-invasive, and 51 high-grade muscle-invasive tumors. We then assessed the relationship between their expression and clinicopathologic features of our patient cohort.
RESULTS: GR was positive in 109 [73.6%; 39 (26.3%) weak (1þ), 39 (26.3%) moderate (2þ), 31 (21.0%) strong (3þ)] tumors, while FOXO1 and p-FOXO1 were positive in 17 [13.2%; 16 (12.4%) 1þ, 1 (0.8%) 2þ] and 71 [55.1%; 57 (44.2%) 1þ, 14 (10.9%) 2þ] tumors, respectively. Eleven (21.6%) low-grade versus 4 (5.1%) high-grade tumors (P¼0.006) and 14 (17.9%) non-muscle-invasive versus 1 (2.0%) muscle-invasive tumors (P¼0.009) showed GR(2þ/3þ)/FOXO1(1þ/ 2þ). Similarly, 3 (5.9%) low-grade versus 31 (39.7%) high-grade tumors (P<0.001) and 12 (15.4%) non-muscle-invasive versus 22 (43.1%) muscle-invasive tumors (P<0.001) showed GR(0/1þ)/p-FOXO1(1þ/ 2þ). Of note, GR expression was positively and negatively associated with FOXO1 (P¼0.002) and p-FOXO1 (P¼0.009), respectively. KaplanMeier and log-rank tests revealed that patients with GR(2þ/3þ) and FOXO1(þ) non-muscle-invasive tumor (N¼14) had a significantly lower risk of tumor recurrence (P¼0.030) and that those with GR(0/1þ) and p-FOXO1(þ) muscle-invasive tumor (N¼22) had a significantly higher risk of disease progression (P¼0.012). Multivariate analysis further revealed combinations of GR and FOXO1 or p-FOXO1 as independent predictors of recurrence of non-muscle-invasive bladder cancer (HR¼0.144; 95%CI¼0.020-1.056; P¼0.057) or progression of muscleinvasive bladder cancer (HR¼2.520; 95%CI¼1.226-5.182; P¼0.012), respectively.
CONCLUSIONS: Activities of GR and FOXO1 appear to be significantly correlated in bladder cancer. Moreover, they precisely predict the prognosis of patients with either non-muscle-invasive or muscle-invasive bladder tumor.
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